Second Sight Medical Products has scored CMS coverage for its new retinal implant designed to treat adults with a degenerative eye disease, a big win for a device company seeking to grow revenue and reach the widest audience possible with its products.
California's Second Sight Medical Products has accomplished a major milestone in the U.S., gaining FDA approval for the first-ever retinal implant here designed to treat adults who have a degenerative eye disease.
Medical device researchers and companies are advancing what was once science fiction in the device and medical equipment realm ever closer to market reality. Even major companies such as Abbott and Boston Scientific are becoming futuristic. Both this year have achieved major milestones with medical devices as ubiquitous as stents and ICDs, updating both products with innovative, life-saving twists. Check out the slideshow >>
In a significant boost for Second Sight Medical Products, an FDA panel of experts has overwhelmingly backed regulatory approval for the company's retinal prosthesis. The Argus II device is now well on its way to becoming the first of its kind approved for use in the U.S.
A positive recommendation for the Argus II device could lead to the U.S.'s first-approved retinal prosthesis hitting shelves.
The U.S. is inching closer to having a retinal prosthesis medical device approved for commercial use. Second Sight Medical Products–one of the few companies in this specialized space–will make its case for the product before the FDA's Ophthalmic Devices Advisory Panel on Sept. 28.
The U.S. Patent and Trademark Office has issued its 8 millionth patent, and the lucky recipient is Second Sight Medical Products for a visual prosthesis apparatus that enhances perception for people
Steve Austin would be proud. Los Angeles-based Second Sight Medical Products may now sell its Argus II retinal prosthesis system in the European Economic Area. And according to The Australian, this